微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 80.49% | -3.2% | 1.37% | 20/159 | -1.59% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 79.4% | -3.5% | -5.04% | 20/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 83.62% | 0.49% | 0.25% | 13/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 83.41% | -2.93% | 0.31% | 16/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 83.15% | -2.84% | 1.06% | 15/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 82.28% | -3.54% | -1.11% | 17/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 83.21% | -3.26% | -3.17% | 14/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 85.93% | -2.58% | 0.41% | 11/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 85.58% | -3.14% | 0.33% | 12/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 85.3% | -3.62% | -0.82% | 10/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 86.01% | -3.74% | -2.48% | 11/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 88.2% | -3.47% | -0.17% | 10/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 88.36% | -4.51% | -0.17% | 9/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 88.5% | -3.46% | -0.95% | 9/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 89.35% | -1.2% | -2.22% | 7/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 91.37% | -0.11% | -1.24% | 10/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 92.52% | 2% | 0.93% | 6/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 91.67% | -0.5% | 1.37% | 7/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 90.43% | 2% | -1.15% | 6/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 91.48% | 2% | -0.7% | 7/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 92.13% | 2% | 2% | 4/159 | 54.11% | 泽璟制药 | 99.96% | 行业排名> |